Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) crossed below its 50 day moving average during trading on Monday after Berenberg Bank lowered their price target on the stock from GBX 2,100 to GBX 2,050. The stock has a 50 day moving average of GBX 1,628.07 and traded as low as GBX 1,625. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals shares last traded at GBX 1,625, with a volume of 1,570,051 shares.
Several other research firms also recently commented on HIK. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,050 to GBX 2,000 and set a “buy” rating on the stock in a research report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,025 price target on shares of Hikma Pharmaceuticals in a research report on Thursday. Finally, Citigroup increased their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a report on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Hikma Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of GBX 1,986.25.
Check Out Our Latest Stock Report on HIK
Hikma Pharmaceuticals Trading Down 1.5%
The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The company’s fifty day moving average is GBX 1,628.07 and its 200-day moving average is GBX 1,509.46. The firm has a market capitalization of £3.36 billion, a P/E ratio of 9.23, a P/E/G ratio of 2.38 and a beta of 0.65.
About Hikma Pharmaceuticals
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
See Also
- Five stocks we like better than Hikma Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
